Key result
SARS-CoV-2 mRNA vaccines linked to small myocarditis or pericarditis risk, highest in men under 40.
Why the study?
Pharmacovigilance revealed a small but significant incidence of myocarditis or pericarditis after SARS-CoV-2 vaccination, prompting a summary of evidence and related guidelines.
SARS-CoV-2 mRNA vaccines are associated with a small but significant risk of myocarditis and pericarditis, predominantly in young men after the second dose.
Answers are grounded in this paper and cite their sources.
Clinicians should discuss rare myocarditis risk with young male recipients; review confirms association yet leaves long-term effects open.
The development of safe and effective vaccines against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was a major turning point in the fight against the Coronavirus 2019 (COVID-19) pandemic. However, pharmacovigilance has revealed a small but significant incidence of cardiac inflammation manifesting clinically as myocarditis or pericarditis, particularly in younger vaccine recipients. The incidence is the highest among men under age 40 within a week of receiving the second dose of the mRNA vaccine. In this review, we summarise the evidence for, and guidelines in relation to, SARS-CoV2 vaccine-related myocarditis.
No takes yet. Share an insight, caveat, or question.
Sularz et al. (2023) conducted a review in SARS-CoV-2 vaccine-related myocarditis. SARS-CoV-2 vaccines was evaluated on myocarditis or pericarditis. SARS-CoV-2 mRNA vaccines are associated with a small incidence of myocarditis or pericarditis, with the highest incidence among men under age 40 within a week of receiving the second dose.
Synapse has enriched 10 related papers. Consider them for comparative context: